Novo Nordisk has completed its acquisition of Akero Therapeutics

Core Points - Novo Nordisk has completed the acquisition of Akero Therapeutics, announced on October 9, 2025, for $54 per share in cash, totaling an aggregated value of $4.7 billion, along with a Contingent Value Right (CVR) that could provide an additional $6 per share upon regulatory approval of Akero's lead candidate EFX [1][2]. Company Overview - Akero Therapeutics is a clinical-stage company focused on developing treatments for serious metabolic diseases, particularly metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate, efruxifermin (EFX), is currently undergoing three Phase 3 clinical studies [5]. - Novo Nordisk is a global healthcare leader founded in 1923, with a mission to combat chronic diseases, particularly diabetes. The company operates in 80 countries and markets its products in around 170 countries [6].